GlobeNewsWire
13 Jun 2026, 01:30 UTC · 4h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
Belite Bio has completed the rolling submission of a New Drug Application (NDA) to the FDA for tinlarebant to treat Stargardt disease type 1 (STGD1). — Moving from clinical trials to a formal NDA submission is a major regulatory milestone that increases the probability of commercialization.
+0.60Tinlarebant has received Breakthrough Therapy Designation (BTD) from the FDA, which may expedite the regulatory review process. — BTD indicates the FDA recognizes the drug's potential to provide a substantial improvement over existing therapies, reducing time-to-market risk.
+0.30There are currently no approved treatment options for STGD1, which affects approximately 53,000 people in the U.S. — The lack of competition for a specific patient population creates a high-potential market opportunity if the drug is approved.
+0.30Continue reading
6 related stories
Top 2 movers · tap to explore
The Phase 3 DRAGON trial demonstrated that tinlarebant significantly reduced the growth rate of retinal lesions compared to a placebo. — Positive Phase 3 data provides the fundamental evidence needed for FDA approval, reducing the risk of a regulatory rejection.
+0.20Which stocks this story touches
The company completed its rolling NDA submission for tinlarebant, a potential first-in-class treatment for Stargardt disease type 1.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
5h ago
